1. Preferential splenic CD8+ T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia
- Author
-
Nona Janikashvili, Christophe Ferrand, V. Leguy, Philippe Saas, Sabine Berthier, Denis Caillot, Laurent Martin, Sylvain Audia, Marc Michel, Bruno Salles, Pablo Ortega-Deballon, Bernard Bonnotte, Bernard Lorcerie, Marion Ciudad, Agnès Soudry-Faure, Nicolas Larmonier, Maxime Samson, Malika Trad, Matthieu Mahévas, Bertrand Godeau, Famky Seaphanh, Alexandrine Gautheron, and Olivier Facy
- Subjects
Adult ,Male ,Immunology ,Drug Resistance ,Spleen ,CD8-Positive T-Lymphocytes ,Lymphocyte Activation ,Real-Time Polymerase Chain Reaction ,Biochemistry ,Pathogenesis ,Antibodies, Monoclonal, Murine-Derived ,Young Adult ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,Immunologic Factors ,Cytotoxic T cell ,Aged ,Aged, 80 and over ,Purpura, Thrombocytopenic, Idiopathic ,biology ,business.industry ,Cell Biology ,Hematology ,T lymphocyte ,Middle Aged ,Immunohistochemistry ,medicine.anatomical_structure ,Monoclonal ,biology.protein ,Female ,Rituximab ,Antibody ,business ,CD8 ,medicine.drug - Abstract
The pathogenic role of B cells in immune thrombocytopenia (ITP) has justified the therapeutic use of anti-CD20 antibodies such as rituximab (RTX). However, 60% of ITP patients do not respond to RTX. To decipher the mechanisms implicated in the failure of RTX, and because the spleen plays a well-recognized role in ITP pathogenesis, 12 spleens from ITP patients who had been nonresponders to RTX therapy were compared with 11 spleens from RTX-untreated ITP patients and 9 controls. We here demonstrate that in RTX-nonresponder ITP patients, preferential Th1 and Tc1 T lymphocyte polarizations occur, associated with an increase in splenic effector memory CD8(+) T-cell frequency. Moreover, in the RTX- nonresponder patient group, the CD8(+) T-cell repertoire displays a restricted pattern. In the blood, the phenotype of CD8(+) T cells before and after RTX treatment is not modified in responders or nonresponders. Altogether, these results demonstrate for the first time an activation of splenic CD8(+) T cells in ITP patients who did not respond to RTX and suggest their involvement in platelet destruction in these patients.
- Published
- 2013